Michael C. Quirk - Apr 1, 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Scientific Officer and Interim Head of R&D
Signature
Brandon Marsh, attorney in fact for Michael C. Quirk
Stock symbol
SAGE
Transactions as of
Apr 1, 2025
Transactions value $
$0
Form type
4
Date filed
4/2/2025, 04:06 PM
Next filing
Apr 11, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +2K +7.38% $0.00 29.1K Apr 1, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE S Award $0 +4K $0.00 4K Apr 1, 2025 Common Stock 4K $7.86 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock issuable under 2,000 restricted stock units ("RSUs"), pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on April 1, 2026, subject to the Reporting Person's continued service.
F2 The option was granted on April 1, 2025, pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. The shares underlying the option vest over four years, with 25% of the shares vesting on April 1, 2026, and the remainder vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Remarks:

Chief Scientific Officer and Interim Head of R&D